2022

Rheonix Receives FDA Clearance for Fully Automated Encompass MDx® Workstation and Molecular Test for Detection of Sexually Transmitted Infections

Low-cost, scalable, sample-to-answer system provides flexibility and true walk-away testing ITHACA, N.Y. — Rheonix Inc., an innovative leader in highly multiplexed pathogen detection, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of its automated Encompass MDx® Workstation, along with its STI TriPlex™ Assay and Male Urine Collection Kit for the detection of sexually transmitted infections (STI). “Rheonix is pleased to announce our FDA 510(k) approval for a… Read More »